Top

Published in:

20-04-2022 | NSCLC | SHORT REPORT

A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report

Authors: Xiang Tian, Qiong Liao, Qidong Yang, Lin Chen, Mingzhe Xiao, Yuanjian Cheng

Published in: Investigational New Drugs | Issue 4/2022

Summary

Genomic fusions of anaplastic lymphoma kinase (ALK) are a well-established therapeutic target in non-small-cell lung cancer (NSCLC). Although various ALK fusion variants have been identified in NSCLC, their responses to ALK tyrosine-kinase inhibitors (TKIs) are heterogeneous. We report the case of a 71-year-old female patient diagnosed with lung adenocarcinoma with liver metastases. A novel CTNND1 (exon 14)-ALK (exon 20) fusion was identified from the biopsy sample by next-generation sequencing (NGS) and validated by immunohistochemistry (IHC) staining. Alectinib was administered, and the patient soon achieved partial response (PR). The progression-free survival (PFS) exceeded 15 months as of January 25, 2022. Our findings expand the spectrum of ALK rearrangements and provide a potential treatment option for lung adenocarcinoma patients with CTNND1-ALK fusions.

Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450–1454. https://doi.org/10.1097/JTO.0b013e3181c4dedbCrossRefPubMed

Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L (2018) Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol 15:694–708. https://doi.org/10.1038/s41571-018-0081-4CrossRefPubMed

Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y (2016) Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol 34:3383–3389. https://doi.org/10.1200/JCO.2015.65.8732CrossRefPubMed

Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Pérol M, Ou SHI, Ahn JS, Shaw AT, Bordogna W, Smoljanović V, Hilton M, Ruf T, Noé J, Peters S (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31:1056–1064. https://doi.org/10.1016/j.annonc.2020.04.478CrossRefPubMed

Camidge DR, Dziadziuszko R, Peters S et al (2019) Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol 14(7):1233–1243. doi:https://doi.org/10.1016/j.jtho.2019.03.007CrossRefPubMed

Sun K, Nie L, Nong L, Cheng Y (2021) Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report. Thorac Cancer 12(12):1927–1930. doi:https://doi.org/10.1111/1759-7714.13983CrossRefPubMedPubMedCentral

Iwahara T, Fujimoto J, Wen D et al (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14(4):439–449. doi:https://doi.org/10.1038/sj.onc.1200849CrossRefPubMed

Hallberg B, Palmer RH (2016) The role of the ALK receptor in cancer biology. Ann Oncol 27(Supplement 3):iii4–iii15. doi:https://doi.org/10.1093/annonc/mdw301CrossRefPubMed

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8(1):11–23. doi:https://doi.org/10.1038/nrc2291CrossRefPubMed

10.

Kong X, Pan P, Sun H et al (2019) Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). J Med Chem 62(24):10927–10954. doi:https://doi.org/10.1021/acs.jmedchem.9b00446CrossRefPubMed

11.

Noé J, Lovejoy A, Ou SHI, Yaung SJ, Bordogna W, Klass DM, Cummings CA, Shaw AT (2020) ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. J Thorac Oncol 15:601–608. https://doi.org/10.1016/j.jtho.2019.10.015CrossRefPubMed

12.

Katayama R, Friboulet L, Koike S et al (2014) Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20(22):5686–5696. doi:https://doi.org/10.1158/1078-0432.CCR-14-1511CrossRefPubMedPubMedCentral

13.

Lin JJ, Zhu VW, Schoenfeld AJ et al (2018) Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol 13(10):1530–1538. doi:https://doi.org/10.1016/j.jtho.2018.06.005CrossRefPubMedPubMedCentral

Title: A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report
Authors: Xiang Tian
Qiong Liao
Qidong Yang
Lin Chen
Mingzhe Xiao
Yuanjian Cheng
Publication date: 20-04-2022
Publisher: Springer US
Keywords: NSCLC
Lung Cancer
Lung Cancer
Tyrosine Kinase Inhibitors
NSCLC
Lung Cancer
Tyrosine Kinase Inhibitors
Alectinib
Published in: Investigational New Drugs / Issue 4/2022
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-022-01245-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2022

A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin

The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA

Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia

Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis

A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer